The following studies are currently recruiting patients Masitinib in prostate cancer The following studies will start recruitment in 2019: Masitinib in Amyotrophic Lateral Sclerosis Masitinib in indolent systemic severe mastocytosis AB8939 in acute myeloid leukemia Patients If you wish to participate in this study, please contact us at the following address:clinical@ab-science.com
22/10/2018 – Final results will be available in 2019.
08/10/2018 – Results published in the Journal of Clinical Investigation Insight further strengthen the body of evidence for masitinib’s mode of action in ALS.
01/10/2018 – AB Science reports its revenues for the first half of 2018 and provides an update on its activities.
23/07/2018 – A trend analysis for OS was planned after a certain number of events are observed.
03/07/2018 – The voting details for each resolution are available in the Investor Relations section of the website.
03/07/2018 – Presentation of the current situation and future prospects.
19/06/2018 – AB Science expects study to be completed in 2019.
28/05/2018 – AB Science is evaluating the possibility to resubmit the application based on the final results from study AB10015.
BOARD OF DIRECTORS The Board of Directors determines the Company’s orientations and oversees their implementation. It deals with all matters concerning the smooth running of the Company and, in its deliberations, matters which concern them. In this context, the Council: Deliberates on the strategy of the Company and the operations there under Appoints corporate…